Skip to main content

Table 1 Demographic and clinical characteristics of patients with and without venous thromboembolism (VTE)

From: Venous thromboembolism and persistent pulmonary hypertension in cancer patients: a cross-sectional study

 

PE n = 48

VTE n = 72

No VTE n = 511

p-value*

Male:female

(47.9):(52.1)

(45.8):(54.2)

(54.4):(45.6)

0.17a

Agex, years

71.3 ± 9.6

70.3 ± 9.8

68.1 ± 11.2

0.11b

Active malignant disease

20/48 (41.7)

30/72 (41.7)

192/511 (37.6)

0.50a

Heart disease

25/48 (52.1)

35/72 (48.6)

197/511 (38.6)

0.10a

 Impaired left ventricular systolic function

3/48 (6.3)

4/72 (5.6)

31/511 (6.1)

1.00c

 Atrial fibrillation

5/48 (10.4)

8/72 (11.1)

83/511 (16.2)

0.26a

 Significant aortic or mitral valve disease

5/48 (10.4)

6/72 (8.3)

40/511 (7.8)

0.88a

 Left ventricular hypertrophy

7/48 (14.6)

14/72 (19.4)

76/511 (14.9)

0.31a

No: mild to moderate: moderately severe: ≥ severe airway obstruction

(63.0):(21.7):(10.9):(4.4)

(70.0):(18.6):(8.6):(2.9)

(62.5):(13.8):(13.0):(10.7)

0.10a

Pulmonary hypertension

16/48 (33.3)

19/72 (26.4)

71/511 (13.9)

<0.01a

  1. *VTE versus No VTE subgroup
  2. Figures in parenthesis are percentages; xmean ± standard deviation; aχ2-Test; bt-test; cFisher’s exact test
  3. Active malignant disease at the time of referral: residual tumor or time interval between surgery/end of chemotherapy/radiotherapy and referral <3 months